271 related articles for article (PubMed ID: 20074076)
1. Progeria, the nucleolus and farnesyltransferase inhibitors.
Mehta IS; Bridger JM; Kill IR
Biochem Soc Trans; 2010 Feb; 38(Pt 1):287-91. PubMed ID: 20074076
[TBL] [Abstract][Full Text] [Related]
2. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
3. Lamin A-linked progerias: is farnesylation the be all and end all?
Smallwood DT; Shackleton S
Biochem Soc Trans; 2010 Feb; 38(Pt 1):281-6. PubMed ID: 20074075
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
6. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
Wang Y; Ostlund C; Worman HJ
Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
[TBL] [Abstract][Full Text] [Related]
7. Medicine. Mouse study suggests cancer drugs could help prematurely aging kids.
Travis J
Science; 2006 Feb; 311(5763):934-5. PubMed ID: 16484462
[No Abstract] [Full Text] [Related]
8. Reversible phenotype in a mouse model of Hutchinson-Gilford progeria syndrome.
Sagelius H; Rosengardten Y; Schmidt E; Sonnabend C; Rozell B; Eriksson M
J Med Genet; 2008 Dec; 45(12):794-801. PubMed ID: 18708427
[TBL] [Abstract][Full Text] [Related]
9. Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment.
Columbaro M; Capanni C; Mattioli E; Novelli G; Parnaik VK; Squarzoni S; Maraldi NM; Lattanzi G
Cell Mol Life Sci; 2005 Nov; 62(22):2669-78. PubMed ID: 16261260
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
[TBL] [Abstract][Full Text] [Related]
11. Genetic and pharmacological modulation of lamin A farnesylation determines its function and turnover.
Foo MXR; Ong PF; Yap ZX; Maric M; Bong CJS; Dröge P; Burke B; Dreesen O
Aging Cell; 2024 May; 23(5):e14105. PubMed ID: 38504487
[TBL] [Abstract][Full Text] [Related]
12. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
McClintock D; Gordon LB; Djabali K
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
[TBL] [Abstract][Full Text] [Related]
13. The truncated prelamin A in Hutchinson-Gilford progeria syndrome alters segregation of A-type and B-type lamin homopolymers.
Delbarre E; Tramier M; Coppey-Moisan M; Gaillard C; Courvalin JC; Buendia B
Hum Mol Genet; 2006 Apr; 15(7):1113-22. PubMed ID: 16481358
[TBL] [Abstract][Full Text] [Related]
14. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
15. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria.
Fong LG; Frost D; Meta M; Qiao X; Yang SH; Coffinier C; Young SG
Science; 2006 Mar; 311(5767):1621-3. PubMed ID: 16484451
[TBL] [Abstract][Full Text] [Related]
16. Protein farnesyltransferase inhibitors and progeria.
Meta M; Yang SH; Bergo MO; Fong LG; Young SG
Trends Mol Med; 2006 Oct; 12(10):480-7. PubMed ID: 16942914
[TBL] [Abstract][Full Text] [Related]
17. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
[TBL] [Abstract][Full Text] [Related]
18. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Meta M; Qiao X; Frost D; Bauch J; Coffinier C; Majumdar S; Bergo MO; Young SG; Fong LG
J Clin Invest; 2006 Aug; 116(8):2115-21. PubMed ID: 16862216
[TBL] [Abstract][Full Text] [Related]
19. Towards a Drosophila model of Hutchinson-Gilford progeria syndrome.
Beard GS; Bridger JM; Kill IR; Tree DR
Biochem Soc Trans; 2008 Dec; 36(Pt 6):1389-92. PubMed ID: 19021561
[TBL] [Abstract][Full Text] [Related]
20. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
